Mechanism of action of antipsychotic drugs: From dopamine D2 receptor antagonism to glutamate NMDA facilitation

Clinical Therapeutics

Volumn 27, Issue SUPPL. 1, 2005, Pages

  Laruelle, Marc ^a   Frankle, W Gordon ^a   Narendran, Rajesh ^a   Kegeles, Lawrence S ^a   Abi Dargham, Anissa ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

Dopamine; Glutamate schizophrenia; PET; Single photon emission computed tomography

Indexed keywords

CLOZAPINE; CYCLOSERINE; DEXTRO SERINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; GLUTAMIC ACID; GLYCINE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PHENCYCLIDINE; RISPERIDONE;

BRAIN CORTEX; CONFERENCE PAPER; CORPUS STRIATUM; DISEASE ASSOCIATION; DOPAMINE RECEPTOR BLOCKING; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG ACTIVITY; DRUG MECHANISM; EXPERIMENT; FACILITATION; HUMAN; NEUROIMAGING; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PLASTICITY; PREFRONTAL CORTEX; SCHIZOPHRENIA; STIMULATION; SYNAPTIC INHIBITION;

ANTIPSYCHOTIC AGENTS; DOPAMINE; DOPAMINE ANTAGONISTS; GLUTAMIC ACID; HUMANS; RECEPTORS, DOPAMINE D2; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 25144509345     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.07.017     Document Type: Conference Paper

References (75)

1. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV 4th ed. 1994 American Psychiatric Association Washington, DC 282
2. Carlsson A, and Lindqvist M Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain Acta Pharmacol Toxicol (Copenh) 20 1963 140 144
3. Seeman P, and Lee T Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons Science 188 1975 1217 1219
4. Creese I, Burt DR, and Snyder SH Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs Science 192 1976 481 483
5. Lieberman JA, Kane JM, and Alvir J. Provocative tests with psychostimulant drugs in schizophrenia Psychopharmacology (Berl) 91 1987 415 433
6. Angrist B, and Van Kammen DP CNS stimulants as tools in the study of schizophrenia Trends Neurosci 7 1984 388 390
7. Olney JW, and Farber NB Glutamate receptor dysfunction and schizophrenia Arch Gen Psychiatry 52 1995 998 1007
8. Javitt DC, and Zukin SR Recent advances in the phencyclidine model of schizophrenia Am J Psychiatry 148 1991 1301 1308
9. Tamminga CA, Holcomb HH, Gao XM, and Lahti AC Glutamate pharmacology and the treatment of schizophrenia: Current status and future directions Int Clin Psychopharmacol. 10 Suppl 3 1995 29 37
10. Goff DC, and Coyle JT The emerging role of glutamate in the pathophysiology and treatment of schizophrenia Am J Psychiatry. 158 2001 1367 1377
11. Jentsch JD, and Roth RH The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia Neuropsychopharmacology 20 1999 201 225
12. Miller DW, and Abercrombie ED Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats Brain Res Bull. 40 1996 57 62
13. Kegeles LS, Abi-Dargham A, and Zea-Ponce Y Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia Biol Psychiatry. 48 2000 627 640
14. Reith J, Benkelfat C, and Sherwin A Elevated dopa decarboxylase activity in living brain of patients with psychosis Proc Natl Acad Sci U S A. 91 1994 11651 11654
15. Hietala J, Syvalahti E, and Vuorio K Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients Lancet 346 1995 1130 1131
16. Dao-Castellana MH, Paillere-Martinot ML, and Hantraye P Presynaptic dopaminergic function in the striatum of schizophrenic patients Schizophr Res. 23 1997 167 174
17. Hietala J, Syvalahti E, and Vilkman H Depressive symptoms and presynaptic dopamine function in neurolepticnaive schizophrenia Schizophr Res. 35 1999 41 50
18. Meyer-Lindenberg A, Miletich RS, and Kohn PD Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia Nat Neurosci 5 2002 267 271
19. McGowan S, Lawrence AD, and Sales T Presynaptic dopaminergic dysfunction in schizophrenia: A positron emission tomographic [18F]fluorodopa study Arch Gen Psychiatry 61 2004 134 142
20. Lindstrom LH, Gefvert O, and Hagberg G Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by l-(beta-11C) DOPA and PET Biol Psychiatry 46 1999 681 688
21. Laruelle M, Abi-Dargham A, and van Dyck CH Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects Proc Natl Acad Sci U S A 93 1996 9235 9240
22. Abi-Dargham A, Gil R, and Krystal J Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort Am J Psychiatry. 155 1998 761 767
23. Laruelle M, Abi-Dargham A, and Gil R Increased dopamine transmission in schizophrenia: Relationship to illness phases Biol Psychiatry 46 1999 56 72
24. Breier A, Su TP, and Saunders R Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method Proc Natl Acad Sci U S A 94 1997 2569 2574
25. Laruelle M The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies Brain Res Brain Res Rev 31 2000 371 384
26. Abi-Dargham A, Rodenhiser J, and Printz D Increased baseline occupancy of D2 receptors by dopamine in schizophrenia Proc Natl Acad Sci U S A 97 2000 8104 8109
27. Krystal JH, Karper LP, and Seibyl JP Subanesthetic effects of the non-competitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch Gen Psychiatry. 51 1994 199 214
28. Lahti AC, Koffel B, LaPorte D, and Tamminga CA Subanesthetic doses of ketamine stimulate psychosis in schizophrenia Neuropsychopharmacology 13 1995 9 19
29. Lahti AC, Weiler MA, and Tamara Michaelidis BA Effects of ketamine in normal and schizophrenic volunteers Neuropsychopharmacology 25 2001 455 467
30. Javitt DC, Zylberman I, and Zukin SR Amelioration of negative symptoms in schizophrenia by glycine Am J Psychiatry 151 1994 1234 1236
31. Javitt DC, Silipo G, and Cienfuegos A Adjunctive high-dose glycine in the treatment of schizophrenia Int J Neuropsychopharmacol. 4 2001 385 391
32. Heresco-Levy U, Javitt DC, and Ermilov M Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia Arch Gen Psychiatry 56 1999 29 36
33. Heresco-Levy U, Javitt DC, and Ermilov M Double-blind, placebocontrolled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia Int J Neuropsychopharmacol 1 1998 131 135
34. Heresco-Levy U, Ermilov M, and Shimoni J Placebo-controlled trial of D- cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia Am J Psychiatry 159 2002 480 482
35. Goff DC, Tsai G, and Levitt J A placebo-controlled trial of D-cycloserine addedto conventional neuroleptics in patients with schizophrenia Arch Gen Psychiatry 56 1999 21 27
36. Tsai G, Yang P, and Chung LC D-serine added to antipsychotics for the treatment of schizophrenia Biol Psychiatry 44 1998 1081 1089
37. Millan MJ N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: A critical review Curr Drug Targets CNS Neurol Disord 1 2002 191 213
38. Harrison PJ The neuropathology of schizophrenia A critical review of the data and their interpretation Brain 122 1999 593 624
39. Meador-Woodruff JH, and Healy DJ Glutamate receptor expression in schizophrenic brain Brain Res Brain Res Rev 31 2000 288 294
40. Konradi C, and Heckers S Molecular aspects of glutamate dysregulation: Implications for schizophrenia and its treatment Pharmacol Ther 97 2003 153 179
41. Carlsson A, Waters N, and Carlsson ML Neurotransmitter interactions in schizophrenia - therapeutic implications Biol Psychiatry 46 1999 1388 1395
42. Jackson ME, Frost AS, and Moghaddam B Stimulation of prefrontal cortex at physiologically relevant frequencies inhibits dopamine release in the nucleus accumbens J Neurochem. 78 2001 920 923
43. Weinberger DR Implications of normal brain development for the pathogenesis of schizophrenia Arch Gen Psychiatry. 44 1987 660 669
44. Adams BW, Bradberry CW, and Moghaddam B NMDA antagonist effects on striatal dopamine release: Microdialysis studies in awake monkeys Synapse 43 2002 12 18
45. Kegeles LS, Martinez D, and Kochan LD NMDA antagonist effects on striatal dopamine release: Positron emission tomography studies in humans Synapse 43 2002 19 29
46. Aalto S, Hirvonen J, and Kajander J Ketamine does not decrease striatal dopamine D2 receptor binding in man Psychopharmacology (Berl) 164 2002 401 406
47. Starr MS Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease Synapse 19 1995 264 293
48. Smith AD, and Bolam JP The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones Trends Neurosci 13 1990 259 265
49. Kotter R Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum Prog Neurobiol 44 1994 163 196
50. Nicola SM, Surmeier J, and Malenka RC Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens Annu Rev Neurosci. 23 2000 185 215
51. Cepeda C, and Levine MS Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum Dev Neurosci 20 1998 1 18
52. Levine MS, Li Z, and Cepeda C Neuromodulatory actions of dopamine on synaptically-evoked neostriatal responses in slices Synapse 24 1996 65 78
53. Centonze D, Picconi B, and Gubellini P Dopaminergic control of synaptic plasticity in the dorsal striatum Eur J Neurosci. 13 2001 1071 1077
54. Cepeda C, Hurst RS, and Altemus KL Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice J Neurophysiol 85 2001 659 670
55. Peris J, Dwoskin LP, and Zahniser NR Biphasic modulation of evoked [3H]D- aspartate release by D-2 dopamine receptors in rat striatal slices Synapse 2 1988 450 456
56. Leveque JC, Macias W, and Rajadhyaksha A Intracellular modulation of NMDA receptor function by antipsychotic drugs J Neurosci 20 2000 4011 4020
57. Onn SP, West AR, and Grace AA Dopamine-mediated regulation of striatal neuronal and network interactions Trends Neurosci. 23 Suppl 10 2000 S48 S56
58. West AR, and Grace AA Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: Studies combining in vivo intracellular recordings and reverse microdialysis J Neurosci. 22 2002 294 304
59. Marti M, Mela F, and Bianchi C Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: Opposite role for D1 and D2 receptors J Neurochem. 83 2002 635 644
60. Morari M, O'Connor WT, Ungerstedt U, and Fuxe K Dopamine D1 and D2 receptor antagonism differentially modulates stimulation of striatal neurotransmitter levels by N-methyl-D-aspartic acid Eur J Pharmacol. 256 1994 23 30
61. Hernandez-Lopez S, Bargas J, and Surmeier DJ D1 receptor activation enhances evoked discharge in neostriatal medium spiny neurons by modulating an L-type Ca2+ conductance J Neurosci 17 1997 3334 3342
62. Flores-Hernandez J, Cepeda C, and Hernandez-Echeagaray E Dopamine enhancement of NMDA currents in dissociated mediumsized striatal neurons: Role of D1receptors and DARPP-32 J Neurophysiol. 88 2002 3010 3020
63. Wilson CJ, and Kawaguchi Y The origins of two-state spontaneous membrane potential fluctuations of neostriatal spiny neurons J Neurosci. 16 1996 2397 2410
64. Dunah AW, and Standaert DG Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane J Neurosci 21 2001 5546 5558
65. Karlsson P, Smith L, and Farde L Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients Psychopharmacology (Berl) 121 1995 309 316
66. Karle J, Clemmesen L, and Hansen L NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia Psychopharmacology (Berl) 121 1995 328 329
67. de Beaurepaire R, Labelle A, and Naber D An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states Psychopharmacology (Berl) 121 1995 323 327
68. Den Boer JA, van Megen HJ, and Fleischhacker WW Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia Psychopharmacology (Berl) 121 1995 317 322
69. 2 receptors in dopamine depleted animals Psychopharmacology (Berl) 135 1998 311 317
70. Jackson DM, Wikstrom H, and Liao Y Is clozapine an (partial) agonist at both dopamine D1 and D2 receptors? Psychopharmacology (Berl) 138 1998 213 216
71. Ahlenius S Clozapine: Dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs Pharmacol Toxicol 84 1999 193 196
72. Farde L, and Nordstrom AL PET examination of central D2 dopamine receptor occupancy in relation to extrapyramidal syndromes in patients being treated with neuroleptic drugs Psychopharmacol Ser. 10 1993 94 100
73. Movin-Osswald G, Nordstrom AL, and Hammarlund-Udenaes M Pharmacokinetics of raclopride formulations. Influence of prolactin and tolerability in healthy male volunteers Clin Pharmacokinet 22 1992 152 161
74. Frankle WG, Gil R, and Hackett E Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: Theoretical implications Psychopharmacology (Berl) 175 2004 473 480
75. Abstract. Strafella AP, Paus T, Barrett J, and Dagher A Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus J Neurosci. 21 2001 RC157